Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma

Diagnostic and Therapeutic Pathway in Diffuse Malignant Peritoneal Mesothelioma

Diffuse malignant peritoneal mesothelioma (DMPM) is a rare form of mesothelioma that carries a very poor prognosis. The 5-year overall survival is about 20% (±5.9). Survival is optimal for patients suitable for cytoreductive surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC), with...

Full description

Bibliographic Details
Main Authors: Shigeki Kusamura, Dario Baratti, Michele De Simone, Enrico Maria Pasqual, Luca Ansaloni, Daniele Marrelli, Manuela Robella, Fabio Accarpio, Mario Valle, Stefano Scaringi, Daniele Biacchi, Carmen Palopoli, Sergio Gazzanelli, Marcello Guaglio, Marcello Deraco
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Cancers
Subjects:
diffuse malignant peritoneal mesothelioma
cytoreductive surgery
HIPEC
Online Access:https://www.mdpi.com/2072-6694/15/3/662

Internet

https://www.mdpi.com/2072-6694/15/3/662

Similar Items